Acquisitions (Schedule Of Valuation Of The Intangible Assets Acquired And Related Amortization Periods) (Details) - USD ($) $ in Thousands		12 Months Ended
	Sep. 25, 2015	Dec. 31, 2016
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation		$ 152,591
Developed Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation		$ 152,591
Par Pharmaceutical Holdings, Inc.
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	$ 3,472,500
Par Pharmaceutical Holdings, Inc. | In-process research and development
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	1,456,700
Par Pharmaceutical Holdings, Inc. | In-process research and development | IPR&D 2019 Launch
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	401,000
Par Pharmaceutical Holdings, Inc. | In-process research and development | IPR&D 2018 Launch
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	283,800
Par Pharmaceutical Holdings, Inc. | In-process research and development | Ezetimibe
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	147,600
Par Pharmaceutical Holdings, Inc. | In-process research and development | IPR&D 2016 Launch
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	133,300
Par Pharmaceutical Holdings, Inc. | In-process research and development | Ephedrine Sulphate
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	128,600
Par Pharmaceutical Holdings, Inc. | In-process research and development | Neostigmine vial
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	118,600
Par Pharmaceutical Holdings, Inc. | In-process research and development | Other IPR&D
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	243,800
Par Pharmaceutical Holdings, Inc. | Developed Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	2,015,800
Par Pharmaceutical Holdings, Inc. | Developed Technology | Vasostrict®
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	$ 556,000
Amortization period	8 years
Par Pharmaceutical Holdings, Inc. | Developed Technology | Aplisol®
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	$ 312,400
Amortization period	11 years
Par Pharmaceutical Holdings, Inc. | Developed Technology | Developed - Other - Non-Partnered (Generic Non-Injectable)
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	$ 230,400
Amortization period	7 years
Par Pharmaceutical Holdings, Inc. | Developed Technology | Developed - Other - Partnered (Combined)
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	$ 164,400
Amortization period	7 years
Par Pharmaceutical Holdings, Inc. | Developed Technology | Nascobal®
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	$ 118,300
Amortization period	9 years
Par Pharmaceutical Holdings, Inc. | Developed Technology | Developed - Other - Non-Partnered (Generic Injectable)
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	$ 116,400
Amortization period	10 years
Par Pharmaceutical Holdings, Inc. | Developed Technology | Other Developed Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	$ 517,900
Amortization period	9 years